Retrospective study of melphalan HDS in patients with cutaneous or uveal melanoma and liver metastases

Trial Profile

Retrospective study of melphalan HDS in patients with cutaneous or uveal melanoma and liver metastases

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Melphalan (Primary) ; Yttrium-90
  • Indications Liver metastases; Malignant melanoma; Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Mar 2015 New trial record
    • 27 Mar 2015 Results presented at Society of Surgical Oncology (SSO) Annual Meeting 2015, according to a Delcath Systems media release.
    • 27 Mar 2015 Results published in Delcath Systems media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top